198 related articles for article (PubMed ID: 34587961)
21. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
22. Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004-2010.
Dalton SO; Steding-Jessen M; Jakobsen E; Mellemgaard A; Østerlind K; Schüz J; Johansen C
Acta Oncol; 2015 May; 54(5):797-804. PubMed ID: 25761702
[TBL] [Abstract][Full Text] [Related]
23. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract][Full Text] [Related]
24. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
25. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
26. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
[TBL] [Abstract][Full Text] [Related]
27. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
28. Influence of socioeconomic factors on survival after breast cancer--a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983-1999.
Dalton SO; Ross L; Düring M; Carlsen K; Mortensen PB; Lynch J; Johansen C
Int J Cancer; 2007 Dec; 121(11):2524-31. PubMed ID: 17680561
[TBL] [Abstract][Full Text] [Related]
29. Changes in employment status up to 5 years after breast cancer diagnosis: A prospective cohort study.
Monteiro I; Morais S; Costa AR; Lopes-Conceição L; Araújo N; Fontes F; Dias T; Pereira S; Lunet N
Breast; 2019 Dec; 48():38-44. PubMed ID: 31493581
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
[TBL] [Abstract][Full Text] [Related]
31. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
33. Loss of partner and breast cancer prognosis - a population-based study, Denmark, 1994-2010.
Olsen MH; Bidstrup PE; Frederiksen K; Rod NH; Grønbaek M; Dalton SO; Johansen C
Br J Cancer; 2012 Apr; 106(9):1560-3. PubMed ID: 22433966
[TBL] [Abstract][Full Text] [Related]
34. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C; Pan H; Godwin J; Gray R; Arriagada R; Raina V; Abraham M; Medeiros Alencar VH; Badran A; Bonfill X; Bradbury J; Clarke M; Collins R; Davis SR; Delmestri A; Forbes JF; Haddad P; Hou MF; Inbar M; Khaled H; Kielanowska J; Kwan WH; Mathew BS; Mittra I; Müller B; Nicolucci A; Peralta O; Pernas F; Petruzelka L; Pienkowski T; Radhika R; Rajan B; Rubach MT; Tort S; Urrútia G; Valentini M; Wang Y; Peto R;
Lancet; 2013 Mar; 381(9869):805-16. PubMed ID: 23219286
[TBL] [Abstract][Full Text] [Related]
37. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Richman J; Ring A; Dowsett M; Sestak I
Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
[TBL] [Abstract][Full Text] [Related]
38. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
[TBL] [Abstract][Full Text] [Related]
39. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
40. Ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study.
Gottschau M; Kjær SK; Viuff JH; Jensen A; Munk C; Settnes A; Mellemkjær L
Breast Cancer Res Treat; 2023 Feb; 197(3):583-591. PubMed ID: 36482232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
